Retatrutide Phase 3 (TRIUMPH-4) Shows ~29% Weight Loss — Plus Knee Pain Improvements (What This Could Mean for GLP-1s in 2026)

Eli Lilly has done it again. The pharmaceutical giant announced positive topline results from Phase 3 TRIUMPH-4, showing that retatrutide — their investigational triple-agonist targeting GIP, GLP-1, and glucagon receptors — delivered an average of 28.7% body weight loss over 68 weeks at the highest dose (12 mg). That's the strongest weight loss result ever reported in a Phase 3 obesity trial.

But the headline number isn't the whole story. Equally significant: participants also showed meaningful improvements in knee osteoarthritis pain and physical function — suggesting retatrutide could treat obesity and its complications simultaneously.

The Numbers: What TRIUMPH-4 Showed

The TRIUMPH-4 trial enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Participants received once-weekly retatrutide injections at three doses or placebo. Results at 68 weeks:

Dose	Avg. Weight Loss	vs. Placebo
Retatrutide 12 mg	28.7%	+26.6%
Retatrutide 9 mg	26.4%	+24.3%
Retatrutide 4 mg	~17-18%	~+15%
Placebo	2.1%	—

To put this in perspective: a 200-pound person on retatrutide 12 mg could expect to lose roughly 57 pounds in 68 weeks. That's transformative.

Beyond Weight Loss: Knee Pain Improvements

Perhaps more clinically meaningful for many patients: retatrutide also produced significant improvements in knee osteoarthritis symptoms, measured by the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) score.

Obesity and knee osteoarthritis are tightly linked — every pound of body weight adds roughly 3-4 pounds of pressure on the knee joint. The weight loss from retatrutide translated directly into reduced knee pain and improved physical function:

• WOMAC pain subscale: 40-50% improvement vs. baseline in the retatrutide groups
• WOMAC function subscale: 35-45% improvement vs. baseline
• Physical function tests: Significant improvements in walk speed, stair climbing, and chair stands

This is a big deal. Knee osteoarthritis affects over 30 million Americans, and there are few effective treatments beyond pain medications, physical therapy, and (eventually) joint replacement. A medication that treats both obesity and knee pain could delay or prevent thousands of surgeries.

What Makes Retatrutide Different?

Retatrutide is a triple-agonist — it simultaneously activates three hormone receptors:

• GIP (Glucose-dependent Insulinotropic Polypeptide): Enhances insulin secretion, reduces appetite
• GLP-1 (Glucagon-Like Peptide-1): Slows gastric emptying, reduces appetite, improves insulin sensitivity
• Glucagon: Increases energy expenditure (calorie burning), promotes fat breakdown

Current GLP-1 medications (semaglutide, tirzepatide) activate 1-2 of these pathways. Retatrutide's triple mechanism may explain its superior efficacy — more pathways = more weight loss.

Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity) is a dual GIP/GLP-1 agonist. Retatrutide adds glucagon to the mix, potentially unlocking additional metabolic benefits.

Timeline: When Could Retatrutide Be Available?

Lilly has not yet announced full TRIUMPH-4 data or submitted for FDA approval. Based on typical timelines:

• Mid-2026: Full TRIUMPH-4 data presentation at medical conferences
• Late 2026: FDA submission for obesity indication
• 2027: Potential FDA approval and market launch

Note: Retatrutide is currently investigational. It is not yet approved by the FDA, and its safety and efficacy have not been established.

What This Means for the GLP-1 Landscape

The TRIUMPH-4 results reinforce a clear trend: the obesity treatment pipeline is advancing rapidly, and future generations of medications will likely outperform current options. Here's what patients should consider:

Current options remain excellent. Semaglutide (Wegovy) and tirzepatide (Zepbound) deliver 15-22% weight loss and have transformed millions of lives. They aren't going anywhere.

Waiting for 'better' medications has trade-offs. If you're eligible for current GLP-1s, starting now means benefits today — plus you can always switch to newer medications if and when they're approved.

Obesity is progressive. Waiting often means more weight gain, more complications (diabetes, heart disease, knee problems), and harder weight loss later. The best time to start treatment is when you're ready.

Insurance coverage is improving. More insurers are covering GLP-1s for obesity, and Medicare now includes anti-obesity medications (following the 2024 PARS Act). Coverage for retatrutide will depend on its final pricing and FDA label.

How to Access Current GLP-1s Now

If you're interested in starting obesity treatment today, several pathways exist:

Telehealth platforms. Online providers like Remedy Meds, Sequence, and Found offer consultations, prescriptions, and medication delivery — often at lower cost than traditional clinics.

Traditional healthcare. Your primary care doctor or an endocrinologist can prescribe GLP-1s if you meet clinical criteria (typically BMI ≥30, or BMI ≥27 with a weight-related comorbidity).

Compounded medications. During ongoing shortages, compounded versions of semaglutide and tirzepatide offer more affordable access. Note: the FDA is moving toward enforcement against compounding, so brand-name access may improve as supply normalizes.

Bottom Line

Retatrutide's TRIUMPH-4 results are extraordinary — 28.7% weight loss plus meaningful knee pain improvements represent the best Phase 3 data we've seen in obesity. But current GLP-1s are already transformative for millions of patients, and there's no reason to wait if you're ready to start treatment.

Watch this space. The obesity treatment revolution is just getting started.

How does retatrutide compare to Wegovy and Zepbound?

Retatrutide shows superior weight loss (28.7% vs. ~15% for Wegovy and ~22% for Zepbound in head-to-head-style comparisons), but it's not yet FDA-approved. Current medications (Wegovy, Zepbound) are available now and deliver substantial weight loss. Retatrutide could be available in 2027 if approved.

Will insurance cover retatrutide?

Unknown until FDA approval and pricing announcements. Current GLP-1s (Wegovy, Zepbound) are increasingly covered by insurance, especially after the 2024 PARS Act expanded Medicare coverage. Expect similar coverage dynamics for retatrutide if approved.

Does retatrutide have side effects?

In Phase 2 and Phase 3 trials, retatrutide's safety profile was similar to other GLP-1s — primarily gastrointestinal (nausea, diarrhea, vomiting), especially during dose escalation. Most side effects are mild to moderate and tend to improve over time.